Trial intelligence / Profile preview

SBRT and Immunotherapy with or without Bevacizumab in Advanced NSCLC

NCT04238169Phase 2

Key facts

Status: Completed
Start: Sep 2020
Primary completion: Dec 2022
Countries: 1
Sponsor: Xinqiao Hospital
Modality: Monoclonal Antibodies

Drugs: bevacizumab
Conditions: non-small cell lung cancer (NSCLC)

Overview

Phase 2, randomised, open-label trial of bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Xinqiao Hospital. Primary endpoints: Objective Response Rate at 6 months and Objective Response of Non-target Lesion at 6 months. Started Sep 2020; status: completed.

Design

2 arms

Study design: RandomizedOpen-label

SBRT+Toripalimab
SBRT (30-50Gy/5F) + Toripalimab (240mg Q3W)
SBRT+Bevacizumab+Toripalimab
SBRT (30-50Gy/5F) + Toripalimab (240mg Q3W) + Bevacizumab (7.5mg/kg Q3W)

Endpoints

Primary

Objective Response Rate6 months
Objective Response of Non-target Lesion6 months

Secondary

Progression-Free Survival2 years
Duration of Response2 years
Overall Survival2 years
Adverse Events2 years

Beyond the preview

Go deeper on NCT04238169.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04238169.